Journal Information
Vol. 6. Issue 6.
Pages 587-594 (November - December 2000)
Share
Share
Download PDF
More article options
Vol. 6. Issue 6.
Pages 587-594 (November - December 2000)
ARTIGO ORIGINAL/ORIGINAL ARTICLE
Open Access
Tuberculose multirresistente: A experiência da Unidade de Tuberculose do Hospital de Pulido Valente
Multidrug-resistant tuberculosis: The impact and management in a Lisbon Tuberculosis Unit
Visits
4169
Carlos Gomes*
* Assistente Hospitalar de Pneumologia com o Grau de Consultor, do Hospital de Pulido Valente
This item has received

Under a Creative Commons license
Article information
RESUMO

Procedemos à anáse retrospectiva da casuística referente ao primeiro ano de actividade da Unidade de Tuberculose do Hospital de Pulido Valente (Abril de 1999 a Abril de 2000), correspondente a 175 internamentos.

Registámos 20 casos de Tuberculose Multirresistente (TB-MR) (11,4%), 10 com Tuberculose Mono resistente (a 1 antibacilar de 1a Unha) (5,7%), 3 com Tuberculose Poliresistente (a 2 ou mais antibacilares de 1a linba, que não Isoniazida e Rifampicina) (1,7%) e 142 doentes com Tuberculose sensível a todos os antibacilares de 1a Unba (81,2%). Comparámos estes quatro grupos com vista à individualização de diferenças significativas relativamente aos seguintes factores comummente associados ao fenómeno da multirresistência: características demográficas, imigração, comportamentos de risco, carga bacilar e esquemas antibacilares prévios (constituição, número e duração).

O número médio de tratamentos prévios foi o único factor associado à TB-MR (2,9), cuja diferençase revelou estatísticamente signiftcativa relativamente aos outros grupos (p<0.001).

No grupo da TB-MR (20 doentes) analisámos os problemas da transmissão nosocomial e da efectividade terapêutica, face aos resultados do antibiograma. Em 11 casos de TB-MR (55%) verificámos que os doentes não estiveram em regime de isolamento. Em 8 casos de TB-MR (40%) a terapêutica antibacilar prescrita ou não teve qualquer eficácia ou redundou em monoterapia.

Concluímos que o número de tratamentos prévios constituíu o principal factor predictivo na TB-MR e que o isolamento sistematico destes doentes bem como o recurso a ténicas de amplificação genétics devem ser mandatórios, face à necessidade imperiosa de um diagnóstico e tratamento precoces das resistências e ao risco aumentado de transmissão de TB-MR.

REV PORT PNEUMOL 2000; VI (6):587-594

Palavras-chave:
Tuberculose multirresistente
Tuberculose pulmonar
Transmissão nosocomial
ABSTRACT

Objective – To compare a group of patients with multidrug-resistant pulmonary tuberculosis (MDR-TB) and patients with various patterns of resistance (including drug-susceptible tuberculosis), and to determine whether there bad been adequate management practices associated with multidrug resistance.

Design – Descriptive study.

Setting – Tuberculosis Unit (Pulido Valente Hospital), Lisbon, Portugal.

Method – The records of all admitted patients between April 1999 and April 2000 were reviewed to ascertain whether there bad been significant differences regarding demographic factors, immigration, HIV status, sputum smear results and prior treatment history and whether the decisions related to therapeutic prescriptions and Isolation care facilities were technically adequate.

Results – Among 175 study patients, 20 MDR-TB were observed (11,4%). The number of prior treatments was the only factor with a statistical significance associated with MDR-TB (average: 2,9 p<0,001). In the MDR-TB group, eleven patients didn't benefit of Isolation care facilities (55%) and 8 patients (40%) were treated with a regimen with less than 2 active antimycobacterial drugs.

Conclusions – Inappropriate or noncompliant prior treatment were associated with MDR-TB. Tighter control on the provisions of Isolation for tuberculosis patients and committing additional laboratory resources (amplification genotypic methods) to standard institutional care are vital in limiting the transmission and development of acquired drug resistance.

REV PORT PNEUMOL 2000; VI (6): 587-594

Key-words:
Multidrug-resistant tuberculosis
Pulmonary tuberculosis
Nosocomial transmission
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
WHO/IUATLD.
Global Project on Anti-tuberculosis Drug-Resistance Surveillance 1994-1997: Anti-Tuberculosis Drug Resistance in the World, (1997),
[2.]
P. Chaulet, M. Raviglione, F. Bustreo.
Epidemiology, control and treatment of Multidrug-resistant Tuberculosis.
Drugs, 52 (1996), pp. 103-108
[3.]
D.L. Cohn, F. Bustreo, M. Raviglione.
Drug-Resistant Tuberculosis: Review of the Worldwide Situation and the WHO/IUATLD Global Surveillance Project.
CID, 24 (1997), pp. S121-S130
[4.]
GLobal Tuberculosis Programme World Health Organization, Geneva.
Guidelines for the Management of Drug-Resistant Tuberculosis, (1997), pp. 210
[5.]
Global Tuberculosis Programme World Health Organization, Geneva.
Treatment of Tuberculosis - Guidelines for National Programmes, (1997),
[6.]
A. Mahmoudi, M.D. Iseman.
Pitfalls in the care of patients with tuberculosis.
JAMA, 270 (1993), pp. 65-68
[7.]
TUBERCULOSIS PROGRAMME WORLD HEALTH ORGANIZATION, GENEVA, AND INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE, PARIS. Guidelines for surveillance of drug resistance in, tuberculosis. WHO/TB/94. 178.
[8.]
L.B. Heifets, G.A. Cangelosi.
Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the tum of the century.
Int J Tuberc Lung Dis, 3 (1999), pp. 564-581
[9.]
A.L. Kritski, et al.
Retreatment Tuberculosis Cases - Factors associated with drug resistance and adverse outcomes.
Chest, 111 (1997), pp. 1162-1167
[10.]
V.W. Lambregts.
Drug-resistanltuberculosis.
Eur Respir Mon, 4 (1997), pp. 298-326
[11.]
DirecçãO Geral da Saúde.
Programa Nacional de Controlo da Tuberculose, (1999), pp. 22-26
[12.]
M.L. Antunes, J. Aleixo-DIAS, A.F. Antunes, M.F. Pereira, E. Raymundo, M.F. Rodrigues.
Anti-tuberculosis drug resistance in Portugal.
Int J Tuberc Lung Dis, 4 (2000), pp. 223-231
[13.]
L.P. Manangan, W.R. Jarvis.
Preventing Multidrug-esistant Tuberculosis and errors in tuberculosis treatment around the globe.
Chest, 117 (2000), pp. 620-623
[14.]
M.D. Iseman.
Management of Multidrug-Resistant Tuberculosis.
Chemotherapy, 45 (1999), pp. 3-11
[15.]
M. Flament-Saillour, J. Robert, V. Jarlier, J. Grosset.
Outcome of Multidrug-Resistant Tuberculosis in France.
Am J Respir Crit Care Med, 160 (1999), pp. 587-593
[16.]
C.W. Spellman, K.J. Matty, S.E. Weis.
A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection.
AIDS, 12 (1998), pp. 191-195
[17.]
R.M. Jasmer, J.A. Hahn, P.M. Small, et al.
A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997.
Ann Intern Med, 130 (1999), pp. 971-978
[18.]
M. Lauzardo, D. Ashkin.
Phthisiology at the dawn of the new century - A review of tuberculosis and the prospects for its elimination.
Chest, 117 (2000), pp. 1455-1473
[19.]
A. Mahmoudi, M.D. Iseman.
Pitfalls in the care of patients with tuberculosis.
JAMA, 270 (1993), pp. 65-68
Copyright © 2000. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?